keyword
MENU ▼
Read by QxMD icon Read
search

vlp formulation

keyword
https://www.readbyqxmd.com/read/28843813/live-baculovirus-acts-as-a-strong-b-and-t-cell-adjuvant-for-monomeric-and-oligomeric-protein-antigens
#1
Suvi Heinimäki, Kirsi Tamminen, Maria Malm, Timo Vesikari, Vesna Blazevic
Recombinant proteins produced by baculovirus (BV) expression systems contain residual BV after crude purification. We studied adjuvant effect of BV on antibody and T cell responses against two model antigens, monomeric ovalbumin (OVA) protein and oligomeric norovirus (NoV) virus-like particles (VLPs). BALB/c mice were immunized intradermally with OVA alone or OVA formulated with live or inactivated BV, and VLP formulations comprised of chromatographically purified NoV GII.4 VLPs alone or mixed with BV, or of crude purified VLPs containing BV impurities from expression system...
August 24, 2017: Virology
https://www.readbyqxmd.com/read/28780375/adjuvant-formulations-for-virus-like-particle-vlp-based-vaccines
#2
REVIEW
Velasco Cimica, Jose M Galarza
The development of virus-like particle (VLP) technology has had an enormous impact on modern vaccinology. In order to optimize the efficacy and safety of VLP-based vaccines, adjuvants are included in most vaccine formulations. To date, most licensed VLP-based vaccines utilize the classic aluminum adjuvant compositions. Certain challenging pathogens and weak immune responder subjects may require further optimization of the adjuvant formulation to maximize the magnitude and duration of the protective immunity...
August 3, 2017: Clinical Immunology: the Official Journal of the Clinical Immunology Society
https://www.readbyqxmd.com/read/28767426/human-papillomavirus-16l1-58l2-chimeric-virus-like-particles-elicit-durable-neutralizing-antibody-responses-against-a-broad-spectrum-of-human-papillomavirus-types
#3
Xue Chen, Hongyang Liu, Zhirong Wang, Shuo Wang, Ting Zhang, Meili Hu, Liang Qiao, Xuemei Xu
The neutralizing antibodies elicited by human papillomavirus (HPV) major capsid protein L1 virus-like particle (VLP)-based vaccines are largely type-specific. An HPV vaccine inducing cross-neutralizing antibodies broadly will be cost-effective and of great value. To this end, we constructed HPV16L1-58L2 chimeric VLP (cVLP) by displaying HPV58 L2 aa.16-37 on the DE surface region of HPV16 L1. We found that vaccination with the HPV16L1-58L2 cVLP formulated with alum plus monophosphoryl lipid A (Alum-MPL) adjuvant elicited robust neutralizing antibodies in both mice and rabbits against all tested HPV types including HPV16/31/33/35/52/58 (genus α9), HPV18/39/45/59/68 (genus α7), HPV6/11 (genus α10), HPV2/27/57 (genus α4), and HPV5 (genus β1)...
July 18, 2017: Oncotarget
https://www.readbyqxmd.com/read/28720462/a-novel-trivalent-hpv-16-18-58-vaccine-with-anti-hpv-16-and-18-neutralizing-antibody-responses-comparable-to-those-induced-by-the-gardasil-quadrivalent-vaccine-in-rhesus-macaque-model
#4
Fei Yin, Yajun Wang, Na Chen, Dunquan Jiang, Yefeng Qiu, Yan Wang, Mei Yan, Jianping Chen, Haijiang Zhang, Yongjiang Liu
Persistent infection with human papillomavirus (HPV) is a key factor in the development of precancerous lesions and invasive cervical cancer. Prophylactic vaccines to immunize against HPV are an effective approach to reducing HPV related disease burden. In this study, we investigated the immunogenicity and dosage effect of a trivalent HPV 16/18/58 vaccine (3vHPV) produced in Escherichia coli (E.coli), with Gardasil quadrivalent vaccine (4vHPV, Merck & Co.) as a positive control. Sera collected from rhesus macaques vaccinated with three dosage formulations of 3vHPV (termed low-, mid-, and high-dosage formulations, respectively), and the 4vHPV vaccine were analyzed by both Pseudovirus-Based Neutralization Assay (PBNA) and Enzyme-Linked Immunosorbent Assay (ELISA)...
June 2017: Papillomavirus Research
https://www.readbyqxmd.com/read/28578824/improving-the-malaria-transmission-blocking-activity-of-a-plasmodium-falciparum-48-45-based-vaccine-antigen-by-spytag-spycatcher-mediated-virus-like-display
#5
Susheel K Singh, Susan Thrane, Christoph M Janitzek, Morten A Nielsen, Thor G Theander, Michael Theisen, Ali Salanti, Adam F Sander
Malaria is a devastating disease caused by Plasmodium parasites, resulting in almost 0.5 million deaths per year. The Pfs48/45 protein exposed on the P. falciparum sexual stages is one of the most advanced antigen candidates for a transmission-blocking (TB) vaccine in the clinical pipeline. However, it remains essential to identify an optimal vaccine formulation that can facilitate induction of a long-lasting TB anti-Pfs48/45 response. Here we report on the development and evaluation of two Pfs48/45-based virus-like particle (VLP) vaccines generated using the AP205 SpyTag/Catcher VLP system...
May 31, 2017: Vaccine
https://www.readbyqxmd.com/read/28545100/intranasal-delivery-of-a-bivalent-norovirus-vaccine-formulated-in-an-in-situ-gelling-dry-powder
#6
Jordan P Ball, Michael J Springer, Yawei Ni, Isaac Finger-Baker, Juan Martinez, Jessica Hahn, John F Suber, Ashley V DiMarco, James D Talton, Ronald R Cobb
The global health community is beginning to understand the burden of norovirus-associated disease, which has a significant impact in both developed and developing countries. Norovirus virus like particle (VLP)-based vaccines are currently under development and have been shown to elicit systemic and mucosal immune responses when delivered intranasally. In the present study, we describe the use of a dry powder formulation (GelVac™) with an in situ gelling polysaccharide (GelSite™) extracted from Aloe vera for nasal delivery of a bivalent vaccine formulation containing both GI and GII...
2017: PloS One
https://www.readbyqxmd.com/read/28481898/zika-virus-like-particle-vlp-based-vaccine
#7
Hélène Boigard, Alexandra Alimova, George R Martin, Al Katz, Paul Gottlieb, Jose M Galarza
The newly emerged mosquito-borne Zika virus poses a major public challenge due to its ability to cause significant birth defects and neurological disorders. The impact of sexual transmission is unclear but raises further concerns about virus dissemination. No specific treatment or vaccine is currently available, thus the development of a safe and effective vaccine is paramount. Here we describe a novel strategy to assemble Zika virus-like particles (VLPs) by co-expressing the structural (CprME) and non-structural (NS2B/NS3) proteins, and demonstrate their effectiveness as vaccines...
May 2017: PLoS Neglected Tropical Diseases
https://www.readbyqxmd.com/read/28468322/virus-like-particle-vlp-plus-microcrystalline-tyrosine-mct-adjuvants-enhance-vaccine-efficacy-improving-t-and-b-cell-immunogenicity-and-protection-against-plasmodium-berghei-vivax
#8
Gustavo Cabral-Miranda, Matthew D Heath, Mona O Mohsen, Ariane C Gomes, Paul Engeroff, Amy Flaxman, Fabiana M S Leoratti, Aadil El-Turabi, Arturo Reyes-Sandoval, Murray A Skinner, Matthias F Kramer, Martin F Bachmann
Vaccination is the most effective prophylactic tool against infectious diseases. Despite continued efforts to control malaria, the disease still generally represents a significant unmet medical need. Microcrystalline tyrosine (MCT) is a well described depot used in licensed allergy immunotherapy products and in clinical development. However, its proof of concept in prophylactic vaccines has only recently been explored. MCT has never been used in combination with virus-like particles (VLPs), which are considered to be one of the most potent inducers of cellular and humoral immune responses in mice and humans...
May 2, 2017: Vaccines
https://www.readbyqxmd.com/read/28321220/adjusted-particle-size-eliminates-the-need-of-linkage-of-antigen-and-adjuvants-for-appropriated-t-cell-responses-in-virus-like-particle-based-vaccines
#9
Ariane C Gomes, Anna Flace, Philippe Saudan, Franziska Zabel, Gustavo Cabral-Miranda, Aadil El Turabi, Vania Manolova, Martin F Bachmann
Since the discovery of the first virus-like particle (VLP) derived from hepatitis B virus in 1980 (1), the field has expanded substantially. Besides successful use of VLPs as safe autologous virus-targeting vaccines, the powerful immunogenicity of VLPs has been also harnessed to generate immune response against heterologous and even self-antigens (2-4). Linking adjuvants to VLPs displaying heterologous antigen ensures simultaneous delivery of all vaccine components to the same antigen-presenting cells. As a consequence, antigen-presenting cells, such as dendritic cells, will process and present the antigen displayed on VLPs while receiving costimulatory signals by the VLP-incorporated adjuvant...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/28257987/delivering-adjuvants-and-antigens-in-separate-nanoparticles-eliminates-the-need-of-physical-linkage-for-effective-vaccination
#10
Mona O Mohsen, Ariane C Gomes, Gustavo Cabral-Miranda, Caroline C Krueger, Fabiana Ms Leoratti, Jens V Stein, Martin F Bachmann
DNA rich in unmethylated CG motifs (CpGs) engage Toll-Like Receptor 9 (TLR-9) in endosomes and are well described stimulators of the innate and adaptive immune system. CpGs therefore can efficiently improve vaccines' immunogenicity. Packaging CpGs into nanoparticles, in particular into virus-like particles (VLPs), improves the pharmacological characteristics of CpGs as the protein shell protects them from DNAse activity and delivers the oligomers to the endosomal compartments of professional antigen presenting cells (APCs)...
February 28, 2017: Journal of Controlled Release: Official Journal of the Controlled Release Society
https://www.readbyqxmd.com/read/28222997/integrated-analysis-of-recombinant-bpv-1-l1-protein-for-the-production-of-a-bovine-papillomavirus-vlp-vaccine
#11
Diego Grando Módolo, Rodrigo Pinheiro Araldi, Jacqueline Mazzuchelli-de-Souza, Alexandre Pereira, Daniel Carvalho Pimenta, Letícia Maria Zanphorlin, Willy Beçak, Marcelo Menossi, Rita de Cassia Stocco, Rodrigo Franco de Carvalho
Bovine papillomatosis is an infectious disease that is caused by bovine papillomavirus (BPV), which results in important economic losses. However, no BPV vaccines or effective treatment methods are commercially available to date. Moreover, the absence of papillomavirus replication in vitro makes the use of recombinant protein a promising candidate for vaccine formulations. Hence, we developed an integrated study on the L1 capsid protein of BPV-1, obtained from a bacterial expression system, regarding its purification, biosafety, thermostability and immunogenicity...
February 17, 2017: Vaccine
https://www.readbyqxmd.com/read/27374905/particle-and-subunit-based-hemagglutinin-vaccines-provide-protective-efficacy-against-h1n1-influenza-in-pigs
#12
Luis A Hernandez, Cathy L Miller, Eric M Vaughn
The increasing diversity of influenza strains circulating in swine herds escalates the potential for the emergence of novel pandemic viruses and highlights the need for swift development of new vaccines. Baculovirus has proven to be a flexible platform for the generation of recombinant forms of hemagglutinin (HA) including subunit, VLP-displayed, and baculovirus-displayed antigens. These presentations have been shown to be efficacious in mouse, chicken, and ferret models but little is known about their immunogenicity in pigs...
August 15, 2016: Veterinary Microbiology
https://www.readbyqxmd.com/read/27354368/rapid-responses-to-2-virus-like-particle-norovirus-vaccine-candidate-formulations-in-healthy-adults-a-randomized-controlled-trial
#13
RANDOMIZED CONTROLLED TRIAL
Robert L Atmar, Frank Baehner, Jakob P Cramer, Eric Song, Astrid Borkowski, Paul M Mendelman
BACKGROUND: Noroviruses pose a significant public health risk, particularly in very young individuals, older adults, and individuals with underlying conditions. We assessed 2 bivalent norovirus virus-like particle (VLP) vaccine candidate formulations in healthy adults aged 18-49 years. METHODS: Enrolled subjects (n = 454) randomly assigned among 3 groups received intramuscular placebo (saline) or vaccines containing either 15 µg or 50 µg of GI.1 VLP and 50 µg GII...
September 15, 2016: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/27340093/virus-like-particle-based-vaccine-against-coxsackievirus-a6-protects-mice-against-lethal-infections
#14
Chaoyun Shen, Zhiqiang Ku, Yu Zhou, Dapeng Li, Lili Wang, Ke Lan, Qingwei Liu, Zhong Huang
Coxsackievirus A6 (CA6) is emerging as one of the major causative agents of hand, foot, and mouth disease (HFMD) worldwide. However, no vaccine is currently available for preventing CA6 infection. Here, we report the development of a virus-like particle (VLP)-based recombinant vaccine for CA6. We produced CA6 VLPs in insect cells by infecting the cells with a baculovirus coexpressing the genes encoding CA6 P1 and 3CD. Biochemical analyses showed that the produced VLPs consisted of VP0, VP1, and VP3 capsid subunit proteins generated by the cleavage of P1 by 3CD...
July 25, 2016: Vaccine
https://www.readbyqxmd.com/read/27147749/broad-cross-protection-is-induced-in-preclinical-models-by-a-human-papillomavirus-vaccine-composed-of-l1-l2-chimeric-virus-like-particles
#15
Mathieu Boxus, Michel Fochesato, Agnès Miseur, Emmanuel Mertens, Najoua Dendouga, Sarah Brendle, Karla K Balogh, Neil D Christensen, Sandra L Giannini
UNLABELLED: At least 15 high-risk human papillomaviruses (HPVs) are linked to anogenital preneoplastic lesions and cancer. Currently, there are three licensed prophylactic HPV vaccines based on virus-like particles (VLPs) of the L1 major capsid protein from HPV-2, -4, or -9, including the AS04-adjuvanted HPV-16/18 L1 vaccine. The L2 minor capsid protein contains HPV-neutralizing epitopes that are well conserved across numerous high-risk HPVs. Therefore, the objective of our study was to assess the capacity to broaden vaccine-mediated protection using AS04-adjuvanted vaccines based on VLP chimeras of L1 with one or two L2 epitopes...
July 15, 2016: Journal of Virology
https://www.readbyqxmd.com/read/27076313/formulation-studies-during-preclinical-development-of-influenza-hemagglutinin-and-virus-like-particle-vaccine-candidates
#16
Newton Wahome, John M Hickey, David B Volkin, C Russell Middaugh
A critical element of vaccine formulation studies is the identification of chemical and physical degradation pathways that compromise structural integrity, and which may in turn affect the clinical safety and efficacy, of macromolecular antigens. Formulation development helps optimize and maintain the long-term storage stability and viability of vaccine antigens in pharmaceutically relevant dosage forms. The protocols presented in this manuscript highlight the use of accelerated stability studies for the formulation of influenza vaccine candidates including virus-like particles (VLP) and particle forming hemagglutinin (HA) antigens...
2016: Methods in Molecular Biology
https://www.readbyqxmd.com/read/27030590/novel-respiratory-syncytial-virus-like-particle-vaccine-composed-of-the-postfusion-and-prefusion-conformations-of-the-f-glycoprotein
#17
Velasco Cimica, Hélène Boigard, Bipin Bhatia, John T Fallon, Alexandra Alimova, Paul Gottlieb, Jose M Galarza
Respiratory syncytial virus (RSV) is the leading cause of severe respiratory disease in infants and children and represents an important global health burden for the elderly and the immunocompromised. Despite decades of research efforts, no licensed vaccine for RSV is available. We have developed virus-like particle (VLP)-based RSV vaccines assembled with the human metapneumovirus (hMPV) matrix protein (M) as the structural scaffold and the RSV fusion glycoprotein (F) in either the postfusion or prefusion conformation as its prime surface immunogen...
June 2016: Clinical and Vaccine Immunology: CVI
https://www.readbyqxmd.com/read/27019231/optimized-formulation-of-a-thermostable-spray-dried-virus-like-particle-vaccine-against-human-papillomavirus
#18
Sugandha Saboo, Ebenezer Tumban, Julianne Peabody, Denis Wafula, David S Peabody, Bryce Chackerian, Pavan Muttil
Existing vaccines against human papillomavirus (HPV) require continuous cold-chain storage. Previously, we developed a bacteriophage virus-like particle (VLP)-based vaccine for HPV infection, which elicits broadly neutralizing antibodies against diverse HPV types. Here, we formulated these VLPs into a thermostable dry powder using a multicomponent excipient system and by optimizing the spray-drying parameters using a half-factorial design approach. Dry-powder VLPs were stable after spray drying and after long-term storage at elevated temperatures...
May 2, 2016: Molecular Pharmaceutics
https://www.readbyqxmd.com/read/26839279/three-duf1996-proteins-localize-in-vacuoles-and-function-in-fungal-responses-to-multiple-stresses-and-metal-ions
#19
Sen-Miao Tong, Ying Chen, Sheng-Hua Ying, Ming-Guang Feng
Many annotated fungal genomes harbour high proportions of hypothetical proteins with or without domains of unknown function (DUF). Here, three novel proteins (342-497 amino acids), each containing only a single large DUF1996 (231-250 residues) region with highly conserved head (DPIXXP) and tail (HXDXXXGW) signatures, were expressed as eGFP-tagged fusion proteins and shown to specifically localize in the vacuoles of Beauveria bassiana, a filamentous fungal entomopathogen; therefore, these proteins were named vacuole-localized proteins (VLPs)...
February 3, 2016: Scientific Reports
https://www.readbyqxmd.com/read/26571021/head-to-head-comparison-of-soluble-vs-q%C3%AE-vlp-circumsporozoite-protein-vaccines-reveals-selective-enhancement-of-nanp-repeat-responses
#20
COMPARATIVE STUDY
Farhat Khan, Mike Porter, Robert Schwenk, Margot DeBot, Philippe Saudan, Sheetij Dutta
Circumsporozoite protein (CSP) of Plasmodium falciparum is a promising malaria vaccine target. RTS,S, the most advanced malaria vaccine candidate consists of the central NANP repeat and carboxy-terminal region of CSP displayed on a hepatitis B virus-like particle (VLP). To build upon the success of RTS,S, we produced a near full-length Plasmodium falciparum CSP that also includes the conserved amino-terminal region of CSP. We recently showed that this soluble CSP, combined with a synthetic Toll-like-receptor-4 (TLR4) agonist in stable oil-in-water emulsion (GLA/SE), induces a potent and protective immune response in mice against transgenic parasite challenge...
2015: PloS One
keyword
keyword
99899
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"